O Blennow1, L Tallstedt, B Hedquist, B Gårdlund. 1. Division of Infectious Diseases, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. ola.blennow@karolinska.se
Abstract
PURPOSE: Few reports have been published on the optimal duration of treatment of ocular candidiasis. We have investigated the incidence of late-onset Candida chorioretinitis and endophthalmitis in patients with candidemia who did not initially receive an ophthalmologic examination. The aim was to determine the duration of initial antifungal treatment that may be sufficient to avoid this complication. METHODS: This was a long-term follow-up study of 144 patients with candidemia who survived for at least 60 days after the onset of candidemia. The frequency of early- and late-onset ocular complications due to candida infection and factors associated with ocular candidiasis were investigated. RESULTS: Fundoscopy was performed on 60 patients, revealing 12 cases of ocular candida infection (20 %). Risk factors were infection with Candida albicans compared to other Candida species (p = 0.021) and surgery due to solid tumor (p = 0.004). Only one case of late-onset ocular candidiasis occurred among the 84 candidemic patients who did not receive an initial ophthalmologic examination. For unknown reasons, this patient had received only 2 days of systemic antifungal treatment initially. CONCLUSIONS: No case of late-onset ocular candidiasis was detected in unexamined patients who received at least 14 days of antifungal treatment. Based on our results, it would appear that the recommended 2 weeks of treatment after the first negative blood culture are sufficient to avoid late-onset complications due to undiscovered Candida chorioretinitis in patients surviving for more than 60 days after the onset of candidemia.
PURPOSE: Few reports have been published on the optimal duration of treatment of ocular candidiasis. We have investigated the incidence of late-onset Candida chorioretinitis and endophthalmitis in patients with candidemia who did not initially receive an ophthalmologic examination. The aim was to determine the duration of initial antifungal treatment that may be sufficient to avoid this complication. METHODS: This was a long-term follow-up study of 144 patients with candidemia who survived for at least 60 days after the onset of candidemia. The frequency of early- and late-onset ocular complications due to candida infection and factors associated with ocular candidiasis were investigated. RESULTS: Fundoscopy was performed on 60 patients, revealing 12 cases of ocular candida infection (20 %). Risk factors were infection with Candida albicans compared to other Candida species (p = 0.021) and surgery due to solid tumor (p = 0.004). Only one case of late-onset ocular candidiasis occurred among the 84 candidemic patients who did not receive an initial ophthalmologic examination. For unknown reasons, this patient had received only 2 days of systemic antifungal treatment initially. CONCLUSIONS: No case of late-onset ocular candidiasis was detected in unexamined patients who received at least 14 days of antifungal treatment. Based on our results, it would appear that the recommended 2 weeks of treatment after the first negative blood culture are sufficient to avoid late-onset complications due to undiscovered Candida chorioretinitis in patients surviving for more than 60 days after the onset of candidemia.
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: C Chalmers; S Gaur; J Chew; T Wright; A Kumar; S Mathur; W Y Wan; I M Gould; A Leanord; A M Bal Journal: Mycoses Date: 2011-05-25 Impact factor: 4.377
Authors: Astrid M L Oude Lashof; Aniki Rothova; Jack D Sobel; Markus Ruhnke; Peter G Pappas; Claudio Viscoli; Haran T Schlamm; Iwona T Oborska; John H Rex; Bart Jan Kullberg Journal: Clin Infect Dis Date: 2011-08-01 Impact factor: 9.079
Authors: S P Donahue; C M Greven; J J Zuravleff; A W Eller; M H Nguyen; J E Peacock; M W Wagener; V L Yu Journal: Ophthalmology Date: 1994-07 Impact factor: 12.079
Authors: Libsen J Rodríguez-Adrián; Robert T King; Luis G Tamayo-Derat; John W Miller; Charles A Garcia; John H Rex Journal: Medicine (Baltimore) Date: 2003-05 Impact factor: 1.889
Authors: A M Tortorano; A Prigitano; C Lazzarini; M Passera; M L Deiana; S Cavinato; C De Luca; A Grancini; G Lo Cascio; C Ossi; E Sala; M T Montagna Journal: Infection Date: 2013-04-05 Impact factor: 3.553
Authors: Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel Journal: Clin Infect Dis Date: 2015-12-16 Impact factor: 9.079
Authors: Antonio Vena; Patricia Muñoz; Belen Padilla; Maricela Valerio; Maria Isabel Sanchez; Mireia Puig-Asensio; Jesus Fortun; Mario Fernandez-Ruiz; Paloma Merino; Juan Emilio Losa; Ana Loza; Rosa Ana Rivas; Emilio Bouza Journal: PLoS One Date: 2017-10-24 Impact factor: 3.240